The fibrin-derived γ377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease

Journal of Experimental Medicine

Volumn 204, Issue 3, 2007, Pages 571-582

  Adams, Ryan A ^a   Bauer, Jan ^b   Flick, Matthew J ^c   Sikorski, Shoana L ^a   Nuriel, Tal ^a,d   Lassmann, Hans ^b   Degen, Jay L ^c   Akassoglou, Katerina ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Medical University of Vienna   (Austria)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; FIBRIN; FIBRINOGEN; INTEGRIN RECEPTOR; P2 C PROTEIN, FIBRINOGEN; P2-C PROTEIN, FIBRINOGEN; PEPTIDE FRAGMENT; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; BLOOD BRAIN BARRIER; BLOOD CLOTTING; CELL ACTIVATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOSKELETON; DEMYELINATING DISEASE; DEMYELINATION; LEUKOCYTE ADHERENCE; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PARALYSIS; PHAGOCYTOSIS; PRIORITY JOURNAL; WESTERN BLOTTING; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CELL CULTURE; FEMALE; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PHYSIOLOGY;

AMINO ACID SEQUENCE; ANIMALS; CELLS, CULTURED; FEMALE; FIBRIN; FIBRINOGEN; MACROPHAGE-1 ANTIGEN; MICE; MICE, INBRED C57BL; MICROGLIA; MOLECULAR SEQUENCE DATA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDE FRAGMENTS;

EID: 33947363967     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20061931     Document Type: Article

References (70)

1. Lassmann, H., W. Bruck, and C. Lucchinetti. 2001. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med. 7:115-121.
2. Platten, M., and L. Steinman. 2005. Multiple sclerosis: trapped in deadly glue. Nat. Med. 11:252-253.
3. Heppner, F.L., M. Greter, D. Marino, J. Falsig, G. Raivich, N. Hovelmeyer, A. Waisman, T. Rulicke, M. Prinz, J. Priller, et al. 2005. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat. Med. 11:146-152.
4. Jack, C., F. Ruffini, A. Bar-Or, and J.P. Antel. 2005. Microglia and multiple sclerosis. J. Neurosci. Res. 81:363-373.
5. Minagar, A., and J.S. Alexander. 2003. Blood-brain barrier disruption in multiple sclerosis. Mult. Scler. 9:540-549.
6. Kermode, A.G., A.J. Thompson, P. Tofts, D.G. MacManus, B.E. Kendall, D.P. Kingsley, I.F. Moseley, P. Rudge, and W.I. McDonald. 1990. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain. 113:1477-1489.
7. Nimmerjahn, A., F. Kirchhoff, and F. Helmchen. 2005. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 308:1314-1318.
8. Claudio, L., C.S. Raine, and C.F. Brosnan. 1995. Evidence of persistent blood-brain barrier abnormalities in chronic-progressive multiple sclerosis. Acta Neuropathol. (Berl.). 90:228-238.
9. Kwon, E.E., and J.W. Prineas. 1994. Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study. J. Neuropathol. Exp. Neurol. 53:625-636.
10. Wakefield, A.J., L.J. More, J. Difford, and J.E. McLaughlin. 1994. Immunohistochemical study of vascular injury in acute multiple sclerosis. J. Clin. Pathol. 47:129-133.
11. Gay, F.W., T.J. Drye, G.W. Dick, and M.M. Esiri. 1997. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain. 120:1461-1483.
12. Tang, L., T.P. Ugarova, E.F. Plow, and J.W. Eaton. 1996. Molecular determinants of acute inflammatory responses to biomaterials. J. Clin. Invest. 97:1329-1334.
13. Languino, L.R., J. Plescia, A. Duperray, A.A. Brian, E.F. Plow, J.E. Geltosky, and D.C. Altieri. 1993. Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway. Cell. 73:1423-1434.
14. Herwald, H., H. Cramer, M. Morgelin, W. Russell, U. Sollenberg, A. Norrby-Teglund, H. Flodgaard, L. Lindbom, and L. Bjorck. 2004. M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell. 116:367-379.
15. Flick, M.J., X. Du, D.P. Witte, M. Jirouskova, D.A. Soloviev, S.J. Busuttil, E.F. Plow, and J.L. Degen. 2004. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J. Clin. Invest. 113:1596-1606.
16. Adams, R.A., M. Passino, B.D. Sachs, T. Nuriel, and K. Akassoglou. 2004. Fibrin mechanisms and functions in nervous system pathology. Mol. Interv. 4:163-176.
17. Flick, M.J., X. Du, and J.L. Degen. 2004. Fibrin(ogen)-alpha M beta 2 interactions regulate leukocyte function and innate immunity in vivo. Exp. Biol. Med. (Maywood). 229:1105-1110.
18. Akassoglou, K., R.A. Adams, J. Bauer, V. Tseveleki, P. Mercado, H. Lassmann, L. Probert, and S. Strickland. 2004. Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis. Proc. Natl. Acad. Sci. USA. 101:6698-6703.
19. Paterson, P.Y. 1976. Experimental allergic encephalomyelitis: role of fibrin deposition in immunopathogenesis of inflammation in rats. Fed. Proc. 35:2428-2434.
20. Coller, B.S. 1997. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J. Clin. Invest. 99:1467-1471.
21. Rotshenker, S. 2003. Microglia and macrophage activation and the regulation of complement-receptor-3 (CR3/MAC-1)-mediated myelin phagocytosis in injury and disease. J. Mol. Neurosci. 21:65-72.
22. van der Laan, L.J., S.R. Ruuls, K.S. Weber, I.J. Lodder, E.A. Dopp, and C.D. Dijkstra. 1996. Macrophage phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-alpha and nitric oxide. J. Neuroimmunol. 70:145-152.
23. Reichert, F., U. Slobodov, C. Makranz, and S. Rotshenker. 2001. Modulation (inhibition and augmentation) of complement receptor-3-mediated myelin phagocytosis. Neurobiol. Dis. 8:504-512.
24. Altieri, D.C., R. Bader, P.M. Mannucci, and T.S. Edgington. 1988. Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen. J. Cell Biol. 107:1893-1900.
25. Lishko, V.K., B. Kudryk, V.P. Yakubenko, V.C. Yee, and T.P. Ugarova. 2002. Regulated unmasking of the cryptic binding site for integrin alpha M beta 2 in the gamma C-domain of fibrinogen. Biochemistry. 41:12942-12951.
26. Fenteany, G., and M. Glogauer. 2004. Cytoskeletal remodeling in leukocyte function. Curr. Opin. Hematol. 11:15-24.
27. Harrison, R.E., and S. Grinstein. 2002. Phagocytosis and the microtubule cytoskeleton. Biochem. Cell Biol. 80:509-515.
28. Ehlers, M.R.W. 2000. CR3: a general purpose adhesion-recognition receptor essential for innate immunity. Microbes Infect. 2:289-294.
29. Ugarova, T.P., D.A. Solovjov, L. Zhang, D.I. Loukinov, V.C. Yee, L.V. Medved, and E.F. Plow. 1998. Identification of a novel recognition sequence for integrin alphaM beta2 within the gamma-chain of fibrinogen. J. Biol. Chem. 273:22519-22527.
30. Lehnardt, S., L. Massillon, P. Follett, F.E. Jensen, R. Ratan, P.A. Rosenberg, J.J. Volpe, and T. Vartanian. 2003. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc. Natl. Acad. Sci. USA. 100:8514-8519.
31. Lehnardt, S., C. Lachance, S. Patrizi, S. Lefebvre, P.L. Follett, F.E. Jensen, P.A. Rosenberg, J.J. Volpe, and T. Vartanian. 2002. The toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. J. Neurosci. 22:2478-2486.
32. Stephens, L., C. Ellson, and P. Hawkins. 2002. Roles of PI3Ks in leukocyte chemotaxis and phagocytosis. Curr. Opin. Cell Biol. 14:203-213.
33. Caron, E., and A. Hall. 1998. Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases. Science. 282:1717-1721.
34. Bell, W.R., S.S. Shapiro, J. Martinez, and H.L. Nossel. 1978. The effects of ancrod, the coagulating enzyme from the venom of Malayan pit viper (A. rhodostoma) on prothrombin and fibrinogen metabolism and fibrinopeptide A release in man. J. Lab. Clin. Med. 91:592-604.
35. Youssef, S., O. Stuve, J.C. Patarroyo, P.J. Ruiz, J.L. Radosevich, E.M. Hur, M. Bravo, D.J. Mitchell, R.A. Sobel, L. Steinman, and S.S. Zamvil. 2002. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 420:78-84.
36. Ugarova, T.P., and V.P. Yakubenko. 2001. Recognition of fibrinogen by leukocyte integrins. Ann. N. Y. Acad. Sci. 936:368-385.
37. Ugarova, T.P., V.K. Lishko, N.P. Podolnikova, N. Okumura, S.M. Merkulov, V.P. Yakubenko, V.C. Yee, S.T. Lord, and T.A. Haas. 2003. Sequence gamma 377-395(P2), but not gamma 190-202(P1), is the binding site for the alpha MI-domain of integrin alpha M beta 2 in the gamma C-domain of fibrinogen. Biochemistry. 42:9365-9373.
38. Ross, T.M., P.M. Martinez, J.C. Renner, R.G. Thorne, L.R. Hanson, and W.H. Frey II. 2004. Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J. Neuroimmunol. 151:66-77.
39. Yura, M., I. Takahashi, S. Terawaki, T. Hiroi, M.N. Kweon, Y. Yuki, and H. Kiyono. 2001. Nasal administration of cholera toxin (CT) suppresses clinical signs of experimental autoimmune encephalomyelitis (EAE). Vaccine. 20:134-139.
40. Xiao, B.G., X.F. Bai, G.X. Zhang, and H. Link. 1998. Suppression of acute and protracted-relapsing experimental allergic encephalomyelitis by nasal administration of low-dose IL-10 in rats. J. Neuroimmunol. 84:230-237.
41. Ishikawa, M., Y. Jin, H. Guo, H. Link, and B.G. Xiao. 1999. Nasal administration of transforming growth factor-beta1 induces dendritic cells and inhibits protracted-relapsing experimental allergic encephalomyelitis. Mult. Scler. 5:184-191.
42. Tran, E.H., H. Hardin-Pouzet, G. Verge, and T. Owens. 1997. Astrocytes and microglia express inducible nitric oxide synthase in mice with experimental allergic encephalomyelitis. J. Neuroimmunol. 74:121-129.
43. Brosnan, C.F., M.B. Bornstein, and B.R. Bloom. 1981. The effects of macrophage depletion on the clinical and pathologic expression of experimental allergic encephalomyelitis. J. Immunol. 126:614-620.
44. Laudano, A.P., and R.F. Doolittle. 1981. Influence of calcium ion on the binding of fibrin amino terminal peptides to fibrinogen. Science. 212:457-459.
45. Vos, C.M., J.J. Geurts, L. Montagne, E.S. van Haastert, L. Bo, P. van der Valk, F. Barkhof, and H.E. de Vries. 2005. Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. Neurobiol. Dis. 20:953-960.
46. Akassoglou, K., and S. Strickland. 2002. Nervous system pathology: the fibrin perspective. Biol. Chem. 383:37-45.
47. Monje, M.L., H. Toda, and T.D. Palmer. 2003. Inflammatory blockade restores adult hippocampal neurogenesis. Science. 302:1760-1765.
48. Brocke, S., C. Piercy, L. Steinman, I.L. Weissman, and T. Veromaa. 1999. Antibodies to CD44 and integrin alpha 4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc. Natl. Acad. Sci. USA. 96:6896-6901.
49. Meyer, A., J. Auernheimer, A. Modlinger, and H. Kessler. 2006. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr. Pharm. Des. 12:2723-2747.
50. Ruoslahti, E. 1996. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 12:697-715.
51. Ruoslahti, E., and M.D. Pierschbacher. 1987. New perspectives in cell adhesion: RGD and integrins. Science. 238:491-497.
52. Vassilev, T.L., M.D. Kazatchkine, J.P. Van Huyen, M. Mekrache, E. Bonnin, J.C. Mani, C. Lecroubier, D. Korinth, D. Baruch, F. Schriever, and S.V. Kaveri. 1999. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood. 93:3624-3631.
53. Inoue, A., C.S. Koh, K. Shimada, N. Yanagisawa, and K. Yoshimura. 1996. Suppression of cell-transferred experimental autoimmune encephalomyelitis in defibrinated Lewis rats. J. Neuroimmunol. 71:131-137.
54. Lock, C., G. Hermans, R. Pedotti, A. Brendolan, E. Schadt, H. Garren, A. Langer-Gould, S. Strober, B. Cannella, J. Allard, et al. 2002. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8:500-508.
55. Cross, A.H., and C.S. Raine. 1991. Central nervous system endothelial cell-polymorphonuclear cell interactions during autoimmune demyelination. Am. J. Pathol. 139:1401-1409.
56. Furtado, G.C., B. Pina, F. Tacke, S. Gaupp, N. van Rooijen, T.M. Moran, G.J. Randolph, R.M. Ransohoff, S.W. Chensue, C.S. Raine, and S.A. Lira. 2006. A novel model of demyelinating encephalomyelitis induced by monocytes and dendritic cells. J. Immunol. 177:6871-6879.
57. Loike, J.D., B. Sodeik, L. Cao, S. Leucona, J.I. Weitz, P.A. Detmers, S.D. Wright, and S.C. Silverstein. 1991. CD11c/CD18 on neutrophils recognizes a domain at the N terminus of the A alpha chain of fibrinogen. Proc. Natl. Acad. Sci. USA. 88:1044-1048.
58. McMahon, E.J., S.L. Bailey, C.V. Castenada, H. Waldner, and S.D. Miller. 2005. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat. Med. 11:335-339.
59. Greter, M., F.L. Heppner, M.P. Lemos, B.M. Odermatt, N. Goebels, T. Laufer, R.J. Noelle, and B. Becher. 2005. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat. Med. 11:328-334.
60. Zhou, H., B.M. Lapointe, S.R. Clark, L. Zbytnuik, and P. Kubes. 2006. A requirement for microglial TLR4 in leukocyte recruitment into brain in response to lipopolysaccharide. J. Immunol. 177:8103-8110.
61. Carson, M.J. 2002. Microglia as liaisons between the immune and central nervous systems: functional implications for multiple sclerosis. Glia. 40:218-231.
62. Lucchinetti, C.F., W. Bruck, M. Rodriguez, and H. Lassmann. 1996. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 6:259-274.
63. Barnett, M.H., A.P. Henderson, and J.W. Prineas. 2006. The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion. Mult. Scler. 12:121-132.
64. Noseworthy, J., D. Miller, and A. Compston. 2006. Disease-modifying treatments in multiple sclerosis. In McAlpine's Multiple Sclerosis. G. Ebers, H. Lassmann, B. Matthews, H. Wekerle, and W.I. MacDonald, editors. Churchill Livingstone, Elsevier, Philadelphia. 729-802.
65. Akassoglou, K., W.-M. Yu, P. Akpinar, and S. Strickland. 2002. Fibrin inhibits peripheral nerve regeneration by arresting Schwann cell differentiation. Neuron. 33:861-875.
66. Karnezis, T., W. Mandemakers, J.L. McQualter, B. Zheng, P.P. Ho, K.A. Jordan, B.M. Murray, B. Barres, M. Tessier-Lavigne, and C.C. Bernard. 2004. The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Nat. Neurosci. 7:736-744.
67. Akassoglou, K., J. Bauer, G. Kassiotis, M. Pasparakis, H. Lassmann, G. Kollias, and L. Probert. 1998. Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am. J. Pathol. 153:801-813.
68. Akassoglou, K., B. Malester, J. Xu, L. Tessarollo, J. Rosenbluth, and M.V. Chao. 2004. Brain-specific deletion of neuropathy target esterase/swisscheese results in neurodegeneration. Proc. Natl. Acad. Sci. USA. 101:5075-5080.
69. Siao, C.J., S.R. Fernandez, and S.E. Tsirka. 2003. Cell type-specific roles for tissue plasminogen activator released by neurons or microglia after excitotoxic injury. J. Neurosci. 23:3234-3242.
70. Seasholtz, T.M., J. Radeff-Huang, S.A. Sagi, R. Matteo, J.M. Weems, A.S. Cohen, J.R. Feramisco, and J.H. Brown. 2004. Rho-mediated cytoskeletal rearrangement in response to LPA is functionally antagonized by Rac1 and PIP2. J. Neurochem. 91:501-512.